Osang Healthcare Co.,Ltd (036220.KQ)
KRW 13080.0
(1.63%)
KRW 13080.0
(1.63%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 219.75 Billion KRW | 127.6% |
| 2022 | 96.55 Billion KRW | 107.78% |
| 2021 | 46.46 Billion KRW | -75.46% |
| 2020 | 189.32 Billion KRW | 1183.11% |
| 2019 | 14.75 Billion KRW | -13.88% |
| 2018 | 17.13 Billion KRW | 1.52% |
| 2017 | 16.87 Billion KRW | -30.13% |
| 2016 | 24.15 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 7.24 Billion KRW | 18.43% |
| 2024 Q1 | 6.12 Billion KRW | 113.54% |
| 2023 Q1 | 194.52 Billion KRW | 1123.25% |
| 2023 Q4 | 2.86 Billion KRW | -36.69% |
| 2023 Q3 | 4.52 Billion KRW | -72.11% |
| 2023 Q2 | 16.23 Billion KRW | -91.65% |
| 2023 FY | 219.75 Billion KRW | 127.6% |
| 2022 Q2 | 24.88 Billion KRW | -43.27% |
| 2022 FY | 96.55 Billion KRW | 107.78% |
| 2022 Q4 | 15.9 Billion KRW | 33.59% |
| 2022 Q3 | 11.9 Billion KRW | -52.17% |
| 2022 Q1 | 43.86 Billion KRW | 439.93% |
| 2021 Q3 | 15.47 Billion KRW | 0.0% |
| 2021 FY | 46.46 Billion KRW | -75.46% |
| 2021 Q4 | 8.12 Billion KRW | -47.49% |
| 2020 FY | 189.32 Billion KRW | 1183.11% |
| 2019 FY | 14.75 Billion KRW | -13.88% |
| 2018 FY | 17.13 Billion KRW | 1.52% |
| 2017 FY | 16.87 Billion KRW | -30.13% |
| 2016 FY | 24.15 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| InBody Co.,Ltd | 128.11 Billion KRW | -71.535% |
| Curexo Inc. | 17.95 Billion KRW | -1123.859% |
| Seegene, Inc. | 180.07 Billion KRW | -22.04% |
| i-SENS, Inc. | 101.04 Billion KRW | -117.495% |
| Ray Co., Ltd. | 65.08 Billion KRW | -237.634% |
| Gencurix Inc. | 422.03 Million KRW | -51971.686% |
| Sugentech Inc. | -5.88 Billion KRW | 3836.862% |
| L&C Bio Co., Ltd | 32.52 Billion KRW | -575.615% |